New hope for myositis: early IVIg may boost recovery
NCT ID NCT05832034
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tests whether adding intravenous immunoglobulin (IVIg) to standard steroid treatment early in myositis helps patients improve faster. Myositis is a group of rare diseases causing muscle inflammation and weakness. The trial includes 44 adults diagnosed within the past year. Participants receive either IVIg or a placebo alongside steroids, and researchers measure muscle strength and disease activity after 12 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Immune Globulin Intravenous (Human) (IVIg, brand name Nanogam)
- What this could lead to
- If this works, it could point toward a faster, more effective way to control myositis early, potentially reducing long-term disability.
- What could go wrong
- This is a small, early-phase trial with only 44 participants, so results may not apply to everyone. IVIg can cause side effects like headaches, allergic reactions, or kidney issues.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANTISYNTHETASE SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Department of Neurology, Amsterdam UMC, location AMC
Amsterdam, North Holland, 1105 AZ, Netherlands
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a targeted immune drug calm rare muscle inflammation?
- Engineered immune cells take aim at Hard-to-Treat muscle disease
- Could a simple injection dissolve painful calcium lumps in rare diseases?
- Engineered immune cells take aim at autoimmune diseases
- Could an arthritis drug help rare lung disease patients?
- HIV drug repurposed to fight muscle inflammation